Cite

    Motzer, R. et al. (2019). Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial. Lancet oncology. 20 (10), pp. 1370-1385. [Online].